DexCom, Inc. $DXCM Holdings Decreased by Baird Financial Group Inc.

Baird Financial Group Inc. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 293,946 shares of the medical device company’s stock after selling 172,134 shares during the period. Baird Financial Group Inc.’s holdings in DexCom were worth $19,797,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC grew its position in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth grew its position in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in DexCom by 1.4% in the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after buying an additional 258 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05. Following the transaction, the executive vice president directly owned 126,043 shares of the company’s stock, valued at $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 65,777 shares of company stock valued at $4,950,714. Company insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $83.03 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm has a market cap of $31.33 billion, a PE ratio of 32.82, a PEG ratio of 1.42 and a beta of 1.42. The firm’s 50 day moving average price is $82.75 and its 200 day moving average price is $72.80. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the firm posted $0.48 earnings per share. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, research analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Mizuho increased their target price on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. JPMorgan Chase & Co. upped their price target on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Citigroup reiterated a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Finally, Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $88.71.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.